{"id":3596724,"date":"2022-04-05T06:45:00","date_gmt":"2022-04-05T10:45:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\/"},"modified":"2025-03-07T23:39:58","modified_gmt":"2025-03-08T04:39:58","slug":"merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\/","title":{"rendered":"Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need"},"content":{"rendered":"<div class=\"q4default\">\n<ul class=\"bwlistdisc\">\n<li>\n    <b><br \/>\n      <i>Late-stage Pipeline and Portfolio Tripled in Size Through Clinical Trial Progress and Business Development Deals Over the Past Year<\/i><br \/>\n    <\/b>\n  <\/li>\n<li>\n    <b><br \/>\n      <i>Eight Potential Approvals Across Cardiovascular Portfolio by 2030, Including Multiple Initial Launches Between 2024-28<\/i><br \/>\n    <\/b>\n  <\/li>\n<li>\n    <b><br \/>\n      <i>Overall Peak Commercial Revenue Opportunity for Portfolio, Including Initial and Future Indications, Expected to Exceed $10 Billion Approaching the Mid-2030s<\/i><br \/>\n    <\/b>\n  <\/li>\n<\/ul>\n<p>    KENILWORTH, N.J.&#8211;(BUSINESS WIRE)&#8211;<br \/>\nMerck (NYSE: MRK), known as MSD outside the United States and Canada, will provide a detailed overview of the company\u2019s broad and growing cardiopulmonary pipeline and portfolio at a virtual meeting with investors today starting at 10:00 AM ET. The company will give further insight into its ongoing late-stage clinical programs in atherosclerosis, heart failure, pulmonary arterial hypertension and thrombosis.\n<\/p>\n<p>\n\u201cCardiovascular disease remains the leading cause of mortality globally, and emerging science is presenting new opportunities to address these unmet medical needs. Merck has created a broad, promising cardiovascular pipeline with the potential to build on our proud legacy in this important field of research, and we are deploying our unique development capabilities and expertise to advance these innovations to patients who need them,\u201d said Dr. Dean Y. Li, president, Merck Research Laboratories.\n<\/p>\n<p>\nDuring the event, leaders from Merck\u2019s research and commercial organizations will outline the company\u2019s strategic priorities in the cardiovascular medicines area. This event is part of Merck\u2019s effort to communicate about its sustainable long-term growth strategy and provide additional insight into the company\u2019s research and development pipeline.\n<\/p>\n<p>\n  <b>Merck Presenters<\/b>\n<\/p>\n<p>\nToday\u2019s event will feature presentations from the following Merck executives:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nEliav Barr, senior vice president, Global Clinical Development and Chief Medical Officer\n<\/li>\n<li>\nArpa Garay, Chief Marketing Officer for Human Health\n<\/li>\n<li>\nJoerg Koglin, vice president, Cardiovascular and Respiratory, Global Clinical Development\n<\/li>\n<li>\nDean Li, president, Merck Research Laboratories\n<\/li>\n<li>\nFiona Marshall, senior vice president, Discovery, Preclinical and Translational Research Sciences\n<\/li>\n<\/ul>\n<p>\nThe full biographies of the speakers may be found <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fevents%2Fmerck-co-inc-cardiovascular-event%2F&amp;esheet=52648361&amp;newsitemid=20220405005473&amp;lan=en-US&amp;anchor=here&amp;index=1&amp;md5=7082814c58fab232591b8be25c33f6c2\">here<\/a> along with the event presentation.\n<\/p>\n<p>\n  <b>Webcast Details<\/b>\n<\/p>\n<p>\nInvestors, analysts, members of the media and the general public are invited to listen to a webcast of the presentation at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Finvestor-relations%2Fevents-and-presentations&amp;esheet=52648361&amp;newsitemid=20220405005473&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Finvestor-relations%2Fevents-and-presentations&amp;index=2&amp;md5=6dbcc157fda9d26e99947d41f6dbaa40\">http:\/\/vip2-msd.com\/merckcom-migrated\/investor-relations\/events-and-presentations<\/a>. Institutional investors and analysts who would like to ask a question during the session should dial in using the information on the events page and follow the operator\u2019s instructions.\n<\/p>\n<p>\n  <b>Merck\u2019s Focus on Cardiovascular and Pulmonary Disease<\/b>\n<\/p>\n<p>\nMerck has a long history of making an impact in cardiovascular disease. More than 60 years ago, we introduced our first cardiovascular therapy \u2013 and our scientific efforts to understand cardiovascular-related disorders have continued. Cardiovascular disease continues to be one of the most serious health challenges of the 21st century. Approximately 18 million people across the globe die every year, and in the United States one person dies every 36 seconds from cardiovascular disease.\n<\/p>\n<p>\nAdvancements in the treatment of cardiovascular and pulmonary disease can make a critical difference for patients around the world. At Merck, we strive for scientific excellence and innovation in all stages of research, from discovery through approval and life cycle management. We work with experts throughout the cardiovascular community to advance research that can help improve the lives of patients globally.\n<\/p>\n<p>\n  <b>About Merck<\/b>\n<\/p>\n<p>\nFor over 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world\u2019s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals \u2013 including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases \u2013 as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Findex.html&amp;esheet=52648361&amp;newsitemid=20220405005473&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=d9abf27fd36657238917023311aef76c\">vip2-msd.com\/merckcom-migrated<\/a> and connect with us on <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=52648361&amp;newsitemid=20220405005473&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=40326ebe8331114efb7ae41f3ade8364\">Twitter<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&amp;esheet=52648361&amp;newsitemid=20220405005473&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=eb7cd428776a633e46dd5c3097474ff2\">Facebook<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&amp;esheet=52648361&amp;newsitemid=20220405005473&amp;lan=en-US&amp;anchor=Instagram&amp;index=6&amp;md5=48bf3be2fe409a46300b05dabc57f9ad\">Instagram<\/a>, <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=52648361&amp;newsitemid=20220405005473&amp;lan=en-US&amp;anchor=YouTube&amp;index=7&amp;md5=98667afe2d0cdb6ae8a0cc3a1c9ecf9c\">YouTube<\/a> and <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=52648361&amp;newsitemid=20220405005473&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=8&amp;md5=4cd281c3c640203346313e04689d81c9\">LinkedIn<\/a>.\n<\/p>\n<p>\n  <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n<\/p>\n<p>\nThis news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company\u2019s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.\n<\/p>\n<p>\nRisks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company\u2019s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company\u2019s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and\/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company\u2019s Annual Report on Form 10-K for the year ended December 31, 2021, and the company\u2019s other filings with the Securities and Exchange Commission (SEC) available at the SEC\u2019s Internet site (<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=52648361&amp;newsitemid=20220405005473&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=9&amp;md5=4f679197fc23cce04dcc76a73b469858\">www.sec.gov<\/a>).\n<\/p>\n<p>\n  <img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220405005473r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\"><br \/>\n  <span class=\"bwct31415\"><\/span>\n<\/p>\n<p id=\"mmgallerylink\">\n  <span id=\"mmgallerylink-phrase\">View source version on <a href=\"http:\/\/businesswire.com\">businesswire.com<\/a>: <\/span><br \/>\n  <span id=\"mmgallerylink-link\"><br \/>\n    <a href=\"https:\/\/www.businesswire.com\/news\/home\/20220405005473\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20220405005473\/en\/<\/a><br \/>\n  <\/span>\n<\/p>\n<p>\nMedia Contacts:\n<\/p>\n<p>\nMelissa Moody<br \/>\n<br \/>(215) 407-3536\n<\/p>\n<p>\nJulie Cunningham<br \/>\n<br \/>(617) 519-6264\n<\/p>\n<p>\nInvestor Contacts:\n<\/p>\n<p>\nPeter Dannenbaum<br \/>\n<br \/>(908) 740-1037\n<\/p>\n<p>\nSteve Graziano<br \/>\n<br \/>(908) 740-6582\n<\/p>\n<p>Source: Merck &amp; Co., Inc.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Late-stage Pipeline and Portfolio Tripled in Size Through Clinical Trial Progress and Business Development Deals Over the Past Year Eight Potential Approvals Across Cardiovascular Portfolio by 2030, Including Multiple Initial Launches Between 2024-28 Overall Peak Commercial Revenue Opportunity for Portfolio, Including Initial and Future Indications, Expected to Exceed $10 Billion Approaching the Mid-2030s Merck (NYSE: MRK), known as MSD outside the United States and Canada, will provide a detailed overview of the company\u2019s broad and growing cardiopulmonary pipeline and portfolio at a virtual meeting with investors today starting at 10:00 AM ET. The company will give further insight into its ongoing late-stage clinical programs in atherosclerosis, heart failure, pulmonary arterial hypertension and thrombosis. \u201cCardiovascular disease remains the leading cause of mortality globally, and emerging science is presenting new opportunities to address these unmet medical needs. Merck has<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-3596724","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Late-stage Pipeline and Portfolio Tripled in Size Through Clinical Trial Progress and Business Development Deals Over the Past Year Eight Potential Approvals Across Cardiovascular Portfolio by 2030, Including Multiple Initial Launches Between 2024-28 Overall Peak Commercial Revenue Opportunity for Portfolio, Including Initial and Future Indications, Expected to Exceed $10 Billion Approaching the Mid-2030s Merck (NYSE: MRK), known as MSD outside the United States and Canada, will provide a detailed overview of the company\u2019s broad and growing cardiopulmonary pipeline and portfolio at a virtual meeting with investors today starting at 10:00 AM ET. The company will give further insight into its ongoing late-stage clinical programs in atherosclerosis, heart failure, pulmonary arterial hypertension and thrombosis. \u201cCardiovascular disease remains the leading cause of mortality globally, and emerging science is presenting new opportunities to address these unmet medical needs. Merck has\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-08T04:39:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220405005473r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\\\/\",\"name\":\"Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220405005473r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2022-04-05T10:45:00+00:00\",\"dateModified\":\"2025-03-08T04:39:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220405005473r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20220405005473r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\/","og_locale":"en_US","og_type":"article","og_title":"Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need - Merck.com","og_description":"Late-stage Pipeline and Portfolio Tripled in Size Through Clinical Trial Progress and Business Development Deals Over the Past Year Eight Potential Approvals Across Cardiovascular Portfolio by 2030, Including Multiple Initial Launches Between 2024-28 Overall Peak Commercial Revenue Opportunity for Portfolio, Including Initial and Future Indications, Expected to Exceed $10 Billion Approaching the Mid-2030s Merck (NYSE: MRK), known as MSD outside the United States and Canada, will provide a detailed overview of the company\u2019s broad and growing cardiopulmonary pipeline and portfolio at a virtual meeting with investors today starting at 10:00 AM ET. The company will give further insight into its ongoing late-stage clinical programs in atherosclerosis, heart failure, pulmonary arterial hypertension and thrombosis. \u201cCardiovascular disease remains the leading cause of mortality globally, and emerging science is presenting new opportunities to address these unmet medical needs. Merck has","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\/","og_site_name":"Merck.com","article_modified_time":"2025-03-08T04:39:58+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220405005473r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\/","name":"Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220405005473r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en","datePublished":"2022-04-05T10:45:00+00:00","dateModified":"2025-03-08T04:39:58+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220405005473r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20220405005473r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-investor-event-today-will-highlight-broad-and-growing-cardiovascular-portfolio-and-pipeline-in-areas-of-unmet-patient-need\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Investor Event Today Will Highlight Broad and Growing Cardiovascular Portfolio and Pipeline in Areas of Unmet Patient Need"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"2652e86e-db82-4950-8306-2376814eddcb","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_multimedia\/Merck_Logo_Horizontal_Teal-Grey_RGB.jpg","size":"211320","File Upload":""}],"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Investor-Event-Today-Will-Highlight-Broad-and-Growing-Cardiovascular-Portfolio-and-Pipeline-in-Areas-of-Unmet-Patient-Need-2022.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/3596724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/3596724\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=3596724"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=3596724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}